Biobank
China's Repository of Primary Cancer Cells from Renewable Sources
Human Living Primary Cell Biobank
Empowering drug discovery with regenerated human primary cells and clinical sample resources.
China's Primary Cell Bank of Recombinant Cancer Cells
Platform Introduction
PRECEDO Biobank is the first living biobank with official approval from the Office of the Administrative Committee for Human Genetic Resources (Approval No.: [2022] BC0101) in China , which is licensed for the collection and preservation of human regenerable resources, including primary cells (PDC), organoids (PDO), and patient-derived xenograft (PDX) models, sourced from clinical cases spanning oncology, normal tissues, immunology, metabolic disorders, and hematologic diseases. PRECEDO biobank provides clinically relevant model systems and big data support for fundamental disease research, target discovery, and drug development.
Construction Situation
The biobank currently consists of 1 main bank and 11 sub-banks, with an annual sample capacity of 15,000+ across 50+ disease types.It includes tumor PDO/PDX models, normal tissue PDO models, and inflammatory disease samples, alongside FFPE blocks and PBMCs, forming a comprehensive platform focused on oncology with multi-disease integration.
sub-banks
samples/year
diseases
models
Sub-Banks Distribution
Hangzhou
Guangzhou
Shenyang
Wuhu
Xian
Shanghai
Shijiazhuang
Qingdao
Jinan
Taiyuan
Hefei
Application Scenario
Basic Cancer Research & Target Discovery
Providing key models and data to advance understanding of tumor biology and identify novel therapeutic targets
Innovative Drug Development
Supporting preclinical efficacy prediction, indication screening, combination therapy optimization, and toxicity evaluation
Precision Oncology
Enabling personalized treatment through accurate drug response testing for cancer patients
Cell Culture Reagents & Factors
Driving innovation in cell culture technologies and associated products
Cell Storage & Cell-Based Therapies
Advancing the development of cell banking and cell-based therapeutic approaches
Future Planning
Through six core technology platforms and six industrial service systems, we deliver accurate, reliable, sustainable, and consistent end-to-end biospecimen solutions to the biopharmaceutical industry.
Construction Situation
The biobank currently consists of 1 main bank and 11 sub-banks, with an annual sample capacity of 10,000+ across 50+ disease types.It includes tumor PDO/PDX models, normal tissue PDO models, and inflammatory disease samples, alongside FFPE blocks and PBMCs, forming a comprehensive platform focused on oncology with multi-disease integration.
Reprogramming Cells, Empowering Medicine
©2026 PRECEDO Biotechnology Co., Ltd. Powered by：www.300.cn